The UK and US have agreed to a key trade agreement that will maintain no duties on British medicine products entering the American market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has pledged to boost funding on pharmaceuticals through the public health system. This move guarantees that import taxes on these crucial exports will be held at zero for a duration of 36 months.
This development follows recent threats to hike duties on branded pharmaceutical products, with figures floated reaching 100%.
"This deal with the UK reinforces the worldwide climate for innovative medicines and brings long-overdue equity to U.S.–U.K. drug exports," a release declared.
Commercial Significance
Pharmaceuticals constitute one of the UK's largest exports to the United States, which is easily the primary market for leading British pharmaceutical firms.
Statistics reveal that in the one-year period leading up to last September, the UK shipped medicines worth over eleven billion pounds to the US. This value accounted for a significant portion of British export trade in that period.
"This agreement secures work, increases investment and paves the way for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary commented.
Detailed UK Commitments
The pact involves several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to double total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The amount drug companies must refund to the NHS to control costs will be capped at 15%. Last year, rebates were more than twenty percent.
Broader Context
The deal follows a protracted row between the sector and the British authorities over medicine costs and approval rates.
The disagreement were exacerbated by arguments that American patients were charged a premium for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several large manufacturing plans in the UK have been halted or abandoned, while substantial investments have been directed toward US facilities.
The Science Minister stated that the NHS had to spend more on treatments, noting that its budget allocation on drugs had declined as a proportion of its overall budget over the last ten years.
